Sociedad Americana de Hirudoterapia

Life without blood: Molecular and functional analysis of hirudins and hirudin-like factors of the Asian non-hematophagous leech Whitmania pigra

Comparative biochemistry published in J Thromb Haemost (2022)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Preclinical (animal)Farmacología salivalGenómica y proteómicaMüller C et al. · Journal of thrombosis and haemostasis : JTH, 2022

Abstract

BACKGROUND: Several leech species of the genera Hirudo, Hirudinaria, and Whitmania are widely used in traditional Chinese medicine (TCM) for the oral treatment of disorders associated with blood stasis. Among them, the non-hematophagous leech Whitmania pigra expresses a variety of components that have the potential to act on the vertebrate blood coagulation system. OBJECTIVE: Whether the thrombin inhibitor hirudin, probably the most prominent leech-derived anticoagulant, is actually present in Whitmania pigra, is still a matter of debate. To answer that open question was the aim of the study. METHODS: We identified several putative hirudin-encoding sequences in transcriptome data of Whitmania pigra. Upon gene synthesis and molecular cloning the respective recombinant proteins were expressed in Escherichia coli, purified, processed, and eventually functionally characterized for thrombin-inhibitory potencies in coagulation assays. RESULTS: We were successful in the identification and functional characterization of several putative hirudins in Whitmania pigra. Some, but not all, of these factors are indeed thrombin inhibitors. Whitmania pigra hence expresses both hirudins (factors that inhibit thrombin) and hirudin-like factors (that do not or only very weakly inhibit thrombin). Furthermore, we revealed the exon/intron structures of the corresponding genes. Coding sequences of some putative hirudins of Whitmania pigra were present also in transcriptome datasets of Hirudo nipponia, a hematophagous leech that is likewise used in TCM. CONCLUSIONS: Based on both structural and functional data we provide very strong evidence for the expression of hirudins in Whitmania pigra. This is the first description of hirudins in a non-hematophagous leech.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAmino Acid SequenceAnimalsAnticoagulantsBlood CoagulationHirudinsLeechesThrombin

Resumen

First description of hirudins in a non-hematophagous leech: multiple putative hirudin sequences identified in Whitmania pigra; recombinant expression confirmed thrombin-inhibitory activity for some, while others were hirudin-like factors with negligible thrombin inhibition.

Por qué esto importa para la hirudoterapia

Este estudio investigó el transcriptoma de la sanguijuela no hematófaga Whitmania pigra para determinar si expresa hirudina, el destacado inhibidor de la trombina. Los investigadores identificaron, clonaron y caracterizaron funcionalmente con éxito varias hirudinas putativas, demostrando que esta sanguijuela no hematófaga efectivamente expresa tanto inhibidores activos de la trombina como factores inactivos tipo hirudina. Esto aporta evidencia molecular fundamental relevante para comprender la biología evolutiva y la diversidad bioquímica del secretoma de las sanguijuelas. Sin embargo, el estudio se limita estrictamente a caracterización molecular y ensayos funcionales in vitro de proteínas recombinantes, sin implicaciones para la práctica clínica ni la hirudoterapia en vivo.

Citación

Life without blood: Molecular and functional analysis of hirudins and hirudin-like factors of the Asian non-hematophagous leech Whitmania pigra.

Müller C et al. · Journal of thrombosis and haemostasis : JTH, 2022

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.